Seeking Alpha·Sep 11, 2026
Agenus Inc. (AGEN) Shareholder/Analyst Call TranscriptAgenus Inc. (AGEN) Shareholder/Analyst Call Transcript
Agenus faces a precarious financial outlook characterized by extreme revenue volatility, where top-line growth is driven by unpredictable milestone payments rather than consistent commercial operations. While the company achieved a 116.3% net margin in 2026Q1,...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.01-122.2% vs $0.04 | $35M+1.5% vs $34M |
Q2 2026 May 11, 2026 | $1.02-51.4% vs $2.10 | $34M-74.0% vs $130M |
Q2 2026 Mar 16, 2026 | $0.56+144.1% vs -$1.27 | $34M+21.7% vs $28M |
Q4 2025 Nov 10, 2025 | $1.94-26.2% vs $2.63 | $30M+7.6% vs $28M |
Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that a poster evaluating botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, has been accepted for presentation at the International Gynecologic Cancer Society (IGCS) Annual Global Meeting, taking place October 1–3, 2026, in Montreal, Canada. The presentation will feature results from the recurre.
Agenus Inc. (NASDAQ: AGEN - Get Free Report)'s stock price passed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $4.36 and traded as high as $8.00. Agenus shares last traded at $7.99, with a volume of 676,249 shares. Analyst Upgrades and Downgrades AGEN has been the
[url="]Agenus[/url] Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Robin Taylor, Ph.D., Chief Commercial Officer, and Zack Ar
Benchmark AGEN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Agenus Inc. (AGEN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $8.70 | $362.29M | -2558.82 | 10.37% | 0.1% | — | — | |
| $60.97 | $2.02B | -6.27 | -43.89% | -287.84% | -37.99% | — | |
| $126.93 | $25.73B | 19.80 | 21.22% | 27.71% | 29.7% | — | |
| $58.15 | $14.62B | 20.92 | 6.98% | 35.33% | 42.49% | — | |
| $26.87 | $3.38B | -8.17 | -4.26% | -386.32% | -87.98% | — | |
| $4.12 | $261.88M | -3.49 | 0.78% | -8.7% | -31.27% | — |
Agenus Inc. (AGEN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Agenus Inc. (AGEN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jul 13, 2026·SEC
Jul 6, 2026·SEC
Get notified when AGEN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Agenus Inc. (AGEN) stock FAQ — growth, dividends, profitability & financials explained
Agenus Inc. (AGEN) reported $132.7M in revenue for fiscal year 2025. This represents a 132593% increase from $0.1M in 1999.
Agenus Inc. (AGEN) grew revenue by 10.4% over the past year. This is steady growth.
Yes, Agenus Inc. (AGEN) is profitable, generating $92.6M in net income for fiscal year 2025 (0.1% net margin).
Agenus Inc. (AGEN) had negative free cash flow of $98.5M in fiscal year 2025, likely due to heavy capital investments.
